Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push MarketBeat - Sun Jun 7, 4:05PM CDT

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the...

CGON : 59.56 (+3.33%)
CG Oncology to Present at Upcoming Investor Conferences in June GlobeNewswire - Thu May 28, 3:05PM CDT

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations...

CGON : 59.56 (+3.33%)
MarketBeat.com
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference MarketBeat - Wed May 20, 9:04PM CDT

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder...

CGON : 59.56 (+3.33%)
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award GlobeNewswire - Tue May 19, 7:00AM CDT

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year’s...

CGON : 59.56 (+3.33%)
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients GlobeNewswire - Fri May 15, 7:00AM CDT

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat...

CGON : 59.56 (+3.33%)
MarketBeat.com
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears MarketBeat - Fri May 15, 2:07AM CDT

CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer...

CGON : 59.56 (+3.33%)
CGON's Billion-Dollar Cash Pile Masking the Absence of a Commercial Product Barchart - Mon May 11, 4:02PM CDT

Barchart Research What to Expect from CGON Earnings CGON Generated May 11, 2026 Current Price $69.32 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 5.32% CGON's Billion-Dollar Cash Pile...

CGON : 59.56 (+3.33%)
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC GlobeNewswire - Mon May 11, 3:15PM CDT

- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth...

CGON : 59.56 (+3.33%)
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Fri May 8, 7:30AM CDT

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026  PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant...

CGON : 59.56 (+3.33%)
CG Oncology to Present at Upcoming Investor Conferences in May GlobeNewswire - Tue May 5, 7:00AM CDT

DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer,...

CGON : 59.56 (+3.33%)

Barchart Exclusives

A $1.24 Trillion Reason to Buy Dell Stock Now Barchart - 11 minutes ago
Dell is riding powerful AI and server tailwinds, steadily expanding market share while growth forecasts keep moving higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.